Torsemide as a Primary Choice in Edema Associated with Heart Failure.


Journal

The Journal of the Association of Physicians of India
ISSN: 0004-5772
Titre abrégé: J Assoc Physicians India
Pays: India
ID NLM: 7505585

Informations de publication

Date de publication:
Sep 2024
Historique:
medline: 18 9 2024
pubmed: 18 9 2024
entrez: 18 9 2024
Statut: ppublish

Résumé

Heart failure (HF) is the fastest-growing disease with a higher fatality rate. The most differentiating feature of HF is pulmonary or peripheral edema, which is characterized by a gradient between intravascular and extravascular pressure. Loop diuretics were chosen as the primary treatment for edema associated with HF due to their efficacy and early onset of action. If an oral dose had not been provided, intravenous (IV) administration of torsemide, or equal doses of furosemide and bumetanide, was preferred. However, the key variables for selecting and administering loop diuretics are their pharmacological qualities as well as their clinical efficacy. Torsemide has greater bioavailability, a higher rate of absorption, a longer duration of action, and lesser ototoxicity, making it the primary choice in the management of edematous HF.

Identifiants

pubmed: 39291568
doi: 10.59556/japi.72.0672
doi:

Substances chimiques

Torsemide W31X2H97FB
Sodium Potassium Chloride Symporter Inhibitors 0
Diuretics 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

19-23

Informations de copyright

© Journal of the Association of Physicians of India 2024.

Auteurs

Janakiraman Ezhilan (J)

Head, Department of Peripheral and Vascular, The Madras Medical Mission Hospital, Chennai, Tamil Nadu, India, Corresponding Author.

Sunil Dighe (S)

Interventional Cardiologist, Department of Cardiology, Medicover Hospital, Sangamner, Mumbai, Maharashtra, India.

Chetan Shah (C)

Senior Consultant Cardiologist and Head, Department of Cardiology, Zynova Shalby Hospital, Mumbai, Maharashtra, India.

Mangesh Tiwaskar (M)

Consultant Physician and Diabetologist, Department of Medicine, Shilpa Medical Research Centre, Mumbai, Maharashtra, India.

Vikas Chopra (V)

Director, Department of Interventional Cardiology, Primus Super Speciality Hospital, Delhi, India.

Rahul Patil (R)

Consultant Interventional Cardiologist, Department of Cardiology, Ruby Hall Clinic, Pune, Maharashtra, India.

Prabin Srivastava (P)

Senior Interventional Cardiologist, Department of Cardiology, RIMS Hospital, Ranchi, Jharkhand, India.

Akshyaya Pradhan (A)

Professor, Department of Cardiology, King George's Medical University, Lucknow, Uttar Pradesh, India.

Suzaur Rahman (S)

Consultant Interventional Cardiologist, Department of Cardiology, Medica Superspecialty Hospital, Kolkata, West Bengal, India.

Amit Malviya (A)

Professor, Department of Cardiology, North Eastern Indira Gandhi Regional Institute of Health and Medical Sciences, Shillong, Meghalaya, India.

Anshuman Gupta (A)

Interventional Cardiologist and Assistant Professor, Department of Cardiology, Dayanand Medical College and Hospital, Ludhiana, Punjab, India.

Phani Teja (P)

Consultant Cardiologist, Department of Cardiology, KIMS Hospital, Rajahmundry, Andhra Pradesh, India.

Febin Francis (F)

Medical Advisor, Medical Affairs, Cipla Ltd., Mumbai, Maharashtra, India.

Amarnath Sugumaran (A)

Cluster Medical Head, Medical Affairs, Cipla Ltd., Mumbai, Maharashtra, India.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH